ACST:CC News and Press, Acasti Pharma Inc. From 09/26/23

PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage ...

PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage ...

New leadership team singularly focused on executing GTX-104 strategy Announced alignment with the U.S. Food and Drug Administration (FDA) for Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 with first patient expected to be dosed prior to the end of 2023 Cash and cash equivalen...

PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104 its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhag...

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange PR Newswire Acasti also confirms no exposure to Silicon Valley Bank ("SVB") or Silvergate Bank LAVAL, Québec , March 13, 2023 /...

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference PR Newswire LAVAL, QC , March 8, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing thr...

Acasti Pharma Recognizes Rare Disease Day PR Newswire LAVAL, QC , Feb. 28, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates ad...

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug ...

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023 PR Newswire Call to be held on Tuesday, February 14th at 1:00 PM Eastern Time LAVAL, QB , Feb. 7, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Comp...

LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces tha...